# Benitec Biopharma (BNTC) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/BNTC
## Company Profile
- Ticker: BNTC
- Exchange: NASDAQ
- Sector: Biopharma
- Location: Australia and listed in the U
- Tags: Nucleic Acid Drugs
## Stock Data
- Close: 12.44 USD
- Market cap: 363468853.72 USD
- Last updated: 2026-09-03
## Business Overview
Benitec Biopharma is a gene-silencing biotechnology company focused on DNA-directed RNA interference and genetic medicine. Its story is built around platform science that aims to durably suppress disease-causing genes.
## Why The Stock Is Moving

As of Sep 3, 2026, BNTC closed down 3.42% at $12.44. No new same-company headline was identified in the current news window.

## Geographic Base

Benitec is headquartered in Australia and listed in the U.S. market. It sits in gene therapy and genetic medicine biotechnology.

## Business Model

The business depends on translational validation, clinical milestones, and the ability to keep a narrow platform funded. Investors watch early data and strategic collaborations.

## Landscape Position

Benitec occupies a gene-silencing niche within biotech. The stock is driven by whether the platform can prove durable and differentiated genetic medicine potential.

## Future Catalysts

- The next few months for Benitec Biopharma are centered on BB-301. The latest company update points to continued work around BB-301 and the next company-specific development update. If that progress holds, the program should stay on the radar through the rest of the quarter.

## Drug Assets

- BB-301

## Recent News
- 2026-05-14 12:00 EST — [Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update](https://biopharmsignal.com/news/BNTC/benitec-biopharma-releases-third-quarter-2026-financial-results-and-provides-operational-update) — Source: Benitec Biopharma
- 2026-04-28 11:00 EST — [Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting](https://biopharmsignal.com/news/BNTC/benitec-biopharma-announces-oral-presentation-of-interim-phase-1b-2a-clinical-study-results-for-high-dose-bb-301-and-continued-durable-improvements-for-low-dose-bb-301-at-the-2026-american-society-of-gene-and-cell-therapy-annual-meeting) — Source: Benitec Biopharma
- 2026-03-10 11:00 EST — [Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD)](https://biopharmsignal.com/news/BNTC/benitec-biopharma-to-host-industry-forum-breakfast-event-at-the-2026-muscular-dystrophy-association-clinical-and-scientific-conference-on-march-10-2026-highlighting-continued-progress-for-bb-301-the-only-clinical-stage-therapeutic-in-development-for-oculopharyngeal-muscular-dystrophy-opmd) — Source: Benitec Biopharma
- 2026-03-09 11:00 EST — [Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference](https://biopharmsignal.com/news/BNTC/benitec-biopharma-announces-positive-interim-phase-1b-2a-results-for-high-dose-bb-301-and-continued-durable-improvements-for-low-dose-bb-301-treatment-at-the-2026-muscular-dystrophy-association-clinical-and-scientific-conference) — Source: Benitec Biopharma
- 2026-02-23 12:00 EST — [Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference](https://biopharmsignal.com/news/BNTC/benitec-biopharma-announces-acceptance-of-late-breaking-abstract-for-the-bb-301-phase-1b-2a-clinical-treatment-study-at-the-muscular-dystrophy-association-clinical-and-scientific-conference) — Source: Benitec Biopharma